Candel Therapeutics, Inc. (CADL) Misses Q4 EPS by 29c

Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q4 EPS of ($0.54), $0.29 worse than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.

You May Also Be Interested In

• Trump: Walmart will be lowering prices
• Franklin Resources reports $1.79 trillion in AUM at end of June
• Barclays Downgrades Siemens Energy AG (ENR:GR) (SMEGF) to Underweight